Cyclacel Limited (CYCC) Announces Publication of Peer-Reviewed Journal Article Describing the Mechanism of Action of Seliciclib
12/30/2009 10:08:36 AM
BERKELEY HEIGHTS, N.J., Dec. 30, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced the publication of an article that reviews and discusses the company's seliciclib (CYC202 or R-roscovitine) product candidate, an orally available inhibitor of multiple cyclin-dependent kinases (CDKs) and its mechanism of action. The peer-reviewed article, "Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs" was published in the online edition of Current Drug Targets.
comments powered by